Compare NCSM & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | PLYX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 114.1M |
| IPO Year | 2017 | N/A |
| Metric | NCSM | PLYX |
|---|---|---|
| Price | $38.70 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.8K | ★ 137.9K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $178,000,000.00 | N/A |
| Revenue This Year | $11.25 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $8.54 | ★ N/A |
| Revenue Growth | ★ 16.49 | N/A |
| 52 Week Low | $23.89 | $2.20 |
| 52 Week High | $53.69 | $48.91 |
| Indicator | NCSM | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | N/A |
| Support Level | $36.03 | N/A |
| Resistance Level | $40.10 | N/A |
| Average True Range (ATR) | 1.53 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 50.00 | 0.00 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.